Price (delayed)
$0.995
Market cap
$89.7M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1
Enterprise value
$54.3M
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's ...
Highlights
The EPS has soared by 57% from the previous quarter and by 53% YoY
The company's debt has shrunk by 59% YoY but it rose by 42% QoQ
Immunic's net income has increased by 31% QoQ but it has decreased by 7% YoY
IMUX's equity has dropped by 55% since the previous quarter and by 36% year-on-year
The quick ratio has contracted by 36% from the previous quarter and by 15% YoY
Key stats
What are the main financial stats of IMUX
MarketValuationsEarnings
Shares outstanding
90.15M
Market cap
$89.7M
Enterprise value
$54.3M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.86
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$98.05M
Net income
-$100.51M
EBIT
-$100.51M
EBITDA
-$100.37M
Free cash flow
-$85.03M
Per shareBalance sheetLiquidity
EPS
-$1
EPS diluted
-$1
Free cash flow per share
-$0.85
Book value per share
$0.2
Revenue per share
$0
TBVPS
$0.41
Total assets
$40.87M
Total liabilities
$22.44M
Debt
$264,000
Equity
$18.43M
Working capital
$17.16M
Debt to equity
0.01
Current ratio
1.77
Quick ratio
1.61
Net debt/EBITDA
0.35
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-135.7%
Return on equity
-194.4%
Return on invested capital
N/A
Return on capital employed
-537.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMUX stock price
How has the Immunic stock price performed over time
Intraday
-5.24%
1 week
-17.08%
1 month
-14.96%
1 year
-19.11%
YTD
-0.5%
QTD
-8.72%
Financial performance
How have Immunic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$98.05M
Net income
-$100.51M
Gross margin
N/A
Net margin
N/A
IMUX financials
IMUX's operating income is up by 34% since the previous quarter
Immunic's net income has increased by 31% QoQ but it has decreased by 7% YoY
Growth
What is Immunic's growth rate over time
IMUX growth chart
Valuation
What is Immunic stock price valuation
P/E
N/A
P/B
4.86
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS has soared by 57% from the previous quarter and by 53% YoY
Price to book (P/B)
The price to book (P/B) is 156% higher than the 5-year quarterly average of 1.9 and 68% higher than the last 4 quarters average of 2.9
IMUX's equity has dropped by 55% since the previous quarter and by 36% year-on-year
Price to sales (P/S)
Efficiency
How efficient is Immunic business performance
The company's return on equity rose by 28% QoQ but it fell by 24% YoY
The company's return on assets rose by 28% QoQ but it fell by 16% YoY
Dividends
What is IMUX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMUX.
Financial health
How did Immunic financials performed over time
Assets vs liabilities
The total assets is 82% greater than the total liabilities
The total assets is down by 37% since the previous quarter and by 25% year-on-year
The quick ratio has contracted by 36% from the previous quarter and by 15% YoY
Debt vs equity
The company's debt is 99% lower than its equity
The company's debt has shrunk by 59% YoY but it rose by 42% QoQ
IMUX's equity has dropped by 55% since the previous quarter and by 36% year-on-year
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.